J&J Paliperidone ER To Go Before Advisory Panel Weeks Before User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm could have an eight-month lead over AstraZeneca’s once-a-day antidepressant.
You may also be interested in...
FDA Cancels Advisory Committee Meeting On J&J’s Paliperidone ER
The company is currently conducting head-to-head trials against AstraZeneca’s antipsychotic Seroquel.
FDA Cancels Advisory Committee Meeting On J&J’s Paliperidone ER
The company is currently conducting head-to-head trials against AstraZeneca’s antipsychotic Seroquel.
Seroquel SR NDA Submitted For Schizophrenia
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.